1 Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing 2 Candidates for COVID-19

- 3 Carmen Mirabelli^{1,*}, Jesse W. Wotring^{2,*}, Charles J. Zhang^{2,†}, Sean M. McCarty^{2,†}, Reid
- 4 Fursmidt^{3,†}, Namrata S. Kadambi³, Anya T. Amin³, Teresa R. O'Meara¹, Carla D. Pretto¹, Tristan
- 5 Frum⁵, Jason R. Spence^{3,5}, Konstantinos D. Alysandratos^{6,7}, Jessie Huang^{6,7}, Darrell N. Kotton^{6,7},
- 6 Christiane E. Wobus¹, Kevin J. Weatherwax^{4,8,9}, George A. Mashour^{4,8,10}, Samuel K.
- 7 Handelman^{3,4}, Matthew J. O'Meara¹¹, Jonathan Z. Sexton^{2,3,4,8}
- ¹Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor,
 MI, 48109, USA
- ²Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI,
 48109, USA
- ¹² ³Department of Internal Medicine, Gastroenterology, Michigan Medicine at the University of ¹³ Michigan, Ann Arbor, MI, 48109, USA
- ⁴U-M Center for Drug Repurposing, University of Michigan, Ann Arbor, MI, 48109, USA
- ⁵Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI, 48109, USA
- ¹⁷ ⁶Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA,
- 18 02118, USA
- ⁷The Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA, 02118, USA
- ⁸Michigan Institute for Clinical and Health Research (MICHR), University of Michigan, Ann Arbor,
 MI, 48109, USA
- ⁹College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA
- ¹⁰Department of Anesthesiology, Michigan Medicine at the University of Michigan, Ann Arbor, MI,
 48109, USA
- ¹¹Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor,
- 27 MI, 48109, USA
- ^{*}These authors contributed equally to this work.
- [†]These authors contributed equally to this work.
- 30

31 Abbreviations:

- 32 MOI: multiplicity of infection
- 33 UMAP: uniform manifold approximation and projection
- 34 COVID-19: Coronavirus Disease-2019
- 35 MOA: mechanism of action
- 36 ROI: region of interest
- iAEC2: induced pluripotent stem cell (iPSC)-derived alveolar epithelial type 2 cells
- 38 HCQ: hydroxychloroquine
- 39
- 40 **Conflicts of interest**
- Jonathan Sexton is the co-founder of Verge Therapeutics, Inc. and owner of Curl Bio, LLC.
- 42
- 43

44 **ABSTRACT**

The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and 45 46 the associated disease COVID-19, requires therapeutic interventions that can be rapidly translated to clinical care. Unfortunately, traditional drug discovery methods have a >90% failure 47 rate and can take 10-15 years from target identification to clinical use. In contrast, drug 48 repurposing can significantly accelerate translation. We developed a quantitative high-throughput 49 50 screen to identify efficacious single agents and combination therapies against SARS-CoV-2. 51 Quantitative high-content morphological profiling was coupled with an AI-based machine learning 52 strategy to classify features of cells for infection and stress. This assay detected multiple antiviral 53 mechanisms of action (MOA), including inhibition of viral entry, propagation, and modulation of 54 host cellular responses. From a library of 1,441 FDA-approved compounds and clinical 55 candidates, we identified 15 dose-responsive compounds with antiviral effects. In particular, we 56 discovered that lactoferrin is an effective inhibitor of SARS-CoV-2 infection with an IC₅₀ of 308 nM 57 and that it potentiates the efficacy of both remdesivir and hydroxychloroguine. Lactoferrin also 58 stimulates an antiviral host cell response and retains inhibitory activity in iPSC-derived alveolar epithelial cells. Given its safety profile in humans, these data suggest that lactoferrin is a readily 59 translatable therapeutic adjunct for COVID-19. Additionally, several commonly prescribed drugs 60 were found to exacerbate viral infection and warrant clinical investigation. We conclude that 61 morphological profiling for drug repurposing is an effective strategy for the selection and 62 optimization of drugs and drug combinations as viable therapeutic options for COVID-19 63 pandemic and other emerging infectious diseases. 64

65 **MAIN**

66 SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA beta-coronavirus that 67 emerged in Wuhan, China in November 2019 and rapidly developed into a global pandemic. The 68 associated disease, COVID-19, has an array of symptoms, ranging from flu-like illness and

gastrointestinal distress^{1,2} to acute respiratory distress syndrome, heart arrhythmias, strokes, and death^{3,4}. Drug repurposing has played an important role in the search for COVID-19 therapies. Recently, the FDA issued emergency approval of remdesivir (GS-5734), a prodrug of a nucleoside inhibitor developed for Ebola virus treatment⁵, and hydroxychloroquine, an aminoquinoline derivative first developed in the 1940s for the treatment of malaria, for patients with severe COVID-19. However, there are no established prophylactic strategies or direct antiviral treatments available to limit SARS-CoV-2 infections and to prevent/cure the associated disease COVID-19.

76

77 Repurposing of FDA-approved drugs is a promising strategy for identifying rapidly deployable 78 treatments for COVID-19. Benefits of repurposing include known safety profiles, robust supply 79 chains, and a short time-frame necessary for development⁶. Additionally, approved drugs serve as chemical probes to understand the biology of viral infection and can make new associations 80 between COVID-19 and molecular targets/pathways that influence pathogenesis of the disease. 81 82 A complementary approach to standard in vitro antiviral assays is high-content imaging-based 83 morphological cell profiling. Using morphological cell profiling, it is possible to identify pathways and novel biology underlying infection, thus allowing for targeted screening around a particular 84 biological process or targeting of host processes that limit viral infection. This enables the 85 86 identification of multiple anti-viral mechanisms, allowing for the rational design of drug combinations or, conversely, revealing drugs that exacerbate infectivity or are associated with 87 cytotoxicity. 88

89

Here, we developed a pipeline for quantitative high-throughput image-based screening of SARS CoV-2 infection. We leveraged machine learning approaches to create an assay metric that
 accurately and robustly identifies features that predict antiviral efficacy and mechanism of action

(MOA). We identified several FDA-approved drugs and clinical candidates with unique antiviral
activity. We further demonstrated that lactoferrin inhibits viral entry and replication, enhances
antiviral host cell response, and potentiates the effects of remdesivir and hydroxychloroquine.
Furthermore, we identified currently prescribed drugs that exacerbate viral infectivity. Collectively,
we present evidence that morphological profiling can robustly identify new potential therapeutics
aqainst SARS-CoV-2 infection as well as drugs that potentially worsen COVID-19 outcomes.

99

100 Morphological profiling reveals unique features associated with SARS-CoV-2 infection

101 To determine the optimal cell line and appropriate endpoint for antiviral drug screening, we 102 assessed SARS-CoV-2 infectivity in previously reported permissive cell lines: Vero-E6, Caco-2, 103 and Huh-7⁷. Viral growth kinetics at a multiplicity of infection (MOI) of 0.2 revealed that Vero-E6, 104 Caco2, and Huh-7 cells supported viral infection, with peak viral titers at 48 hours post infection (hrs p.i.) (Supplementary Figure 1A/B). Although the viral load was higher in Vero-E6 cells, Huh-105 7 were selected for our morphological drug screen as a human cell line that expresses both ACE2 106 107 and TMPRSS2, which are the primary entry factors for SARS-CoV-2⁸. Infection was detectable in Huh-7 cells at an MOI as low as 0.004 at 48 hrs p.i. (Supplementary Figure 1C), which highlights 108 the high sensitivity of image-based screening. To identify compounds that inhibit or exacerbate 109 infection, we selected an MOI of 0.2, leading to a baseline infectivity rate of 20%. 110

111

Morphological cell profiling was enabled through multiplexed staining and automated high-content fluorescence microscopy. Our multiplexed dye set included markers for SARS-CoV-2 nucleocapsid protein, nuclei (Hoechst 33342), neutral lipids (HCS LipidTox Green), and cell boundaries (HCS CellMask Orange). These fluorescent probes were chosen to capture a wide variety of cellular features relevant to viral infectivity, including nuclear morphology, nuclear

117 texture, cytoplasmic and cytoskeletal features, and indicators of cell health. From our initial 118 profiling we observed three prominent morphological features associated with SARS-CoV-2 119 infection: the formation of syncytia, increased nucleoli count (Supplementary Figure 1D), and 120 cytoplasmic protrusions (Figure 1). These features, which are key indicators of SARS-CoV-2 121 infection in Huh-7, were used to generate our machine learning pipeline for antiviral drug 122 discovery.

123

124 Machine learning identifies FDA-approved molecules with antiviral activity against SARS-

125 **CoV-2**

126 To identify compounds with antiviral activity against SARS-CoV-2, we screened a custom library 127 of 1,441 FDA-approved compounds and rationally included clinical candidates in Huh-7 cells 128 (Supplementary File 1). Compounds were assessed for their antiviral activity using a CellProfilerbased image analysis pipeline and a random forest classification algorithm to identify infected 129 cells and quantify their morphological characteristics (Figure 2A). The random forest classifier 130 leveraged 660 unique cellular features including measurements of intensity, texture and radial 131 distribution for each fluorescent channel (nuclei, cytoplasm, lipid, virus). From the primary 132 quantitative high-throughput screening (gHTS), hits were defined as compounds with consistent 133 decreases in viral infectivity in at least three of the tested concentrations (50 nM, 250 nM, 500 nM, 134 135 1000 nM and 2000 nM) as well as minimal cytotoxicity. This approach for hit identification was 136 intentionally designed to be broad to minimize false negatives and maximize our list of efficacious 137 compounds which would later be refined. Our first-pass gHTS approach identified 132 compounds with moderate dose-responsive antiviral behavior between 50 nM and 2 µM, and successfully 138 139 eliminated compounds without any significant activity or obvious cytotoxicity.

141 In confirmatory screening, 10-point, two-fold dilution dose-response experiments were performed in triplicate on the 132 gHTS hits, with validation of dose-responsive efficacy for 15 compounds 142 below 1 µM potency (Supplementary Table 1 and Figure 2B). These hits include nine that are 143 144 novel in vitro observations (lactoferrin, S1RA, entecavir, lomitapide, metoclopramide, bosutinib, 145 thioguanine, fedratinib, and Z-FA-FMK), and six that have been previously identified to have antiviral activity (amiodarone, verapamil, gilteritinib, clofazimine^{9,10}, niclosamide¹¹, and 146 147 remdesivir). In addition to antiviral drug hits, we also identified several compounds that appear to exacerbate SARS-CoV-2 infection, including trametinib, binimetinib and cobimetinib -potent MEK 148 inhibitors used to treat metastatic melanoma- and the Parkinson's disease drugs carbidopa, 149 150 methyldopa and levodopa (Supplementary Figure 2).

151

152 Cell level feature clustering reveals potential mechanisms of action for lead compounds

In contrast to standard single-endpoint in vitro assays, morphological cell profiling allows for the 153 efficient visualization and quantitation of biological characteristics of viral infection and cytotoxicity. 154 To assist with mechanistic determination, we used dimensionality reduction via the non-linear 155 uniform manifold approximation and projection (UMAP) embedding, which projects the cellular 156 feature vector into a 2-dimensional plot to observe clusters of cells based on their distinct 157 morphological features¹². Millions of cells were observed in the UMAP embedding through a range 158 159 of drug concentrations alongside negative and positive controls to observe perturbations in 160 specific morphological clusters (Supplementary Figure 3B).

In the UMAP embedding, we identified 15 regions of interest (ROI) with high cell density (Figure 3B). A broad density region (ROIs 10,15) contained uninfected cells with satellite populations having characteristic morphologies including cell division (ROI 6) and accumulation of lipids towards the periphery of the cell (ROI 12). A large disconnected region (ROIs 1-4) contained 165 individually infected cells (ROI 4), infected cells in syncytia (ROI 3), and cells adjacent to infected cells (ROIs 1,2) (Figure 3C). Pseudotime of the viral infection progression can be inferred through 166 inspection of cluster populations where cells begin in the main cluster body (ROIs 10,15) and 167 traverse to the infected cluster (ROIs 1-4) where there is punctate viral signal (ROI 1) which 168 169 progress to isolated infected cells characterized by homogenous nucleocapsid staining throughout the cytoplasm (ROI 2), and ends with infection of surrounding cells and the formation 170 of syncytia (ROIs 3,4). All efficacious compounds deplete ROIs 1-4 and thioguanine, clofazimine, 171 172 S1RA and gilteritinib show differences in the UMAP cluster dynamics (Supplementary Figure 3B) suggestive of differing MOAs. 173

174

175 Lactoferrin blocks SARS-CoV-2 replication at different stages of the viral cycle

176 One of the most efficacious hits identified from our screen was lactoferrin, a protein found in milk and other secretory fluids¹³. We determined that lactoferrin has dose-dependent antiviral activity 177 through a range of MOIs (Figure 4A and B). Previous work on lactoferrin in the context of infection 178 179 with SARS-CoV-1 suggests that it blocks viral entry by binding heparan sulfate proteoglycans that are important for early viral attachment¹³. Our studies showed that lactoferrin blocks SARS-CoV-180 2 infection through entry inhibition and is also capable of rescuing infection when added 1 or 24 181 hrs p.i. (Figure 4B). Lactoferrin has been proposed to enhance innate interferon responses to limit 182 viral replication within host cells¹⁴. Upon treatment, we observed a dose-dependent reduction of 183 184 viral replication (Figure 4C), which was consistent with elevated mRNA levels of IFNB and 185 interferon-stimulated genes (ISG15, MX1, Viperin and IFITM3) in lactoferrin-treated Huh-7 cells (Figure 4D). Interestingly, we detected a robust antiviral effect by both holo and apolactoferrin, 186 187 the latter being the component of widely available dietary supplements. To rule out a mode of action that involved a general iron depletion mechanism, we tested the protein transferrin and 188

found that it was devoid of any anti-SARS-CoV-2 activity at the highest concentration of 2.3 μM (Figure 4E). Lastly, we tested the efficacy of lactoferrin in physiologically relevant iPSC-derived alveolar epithelial type 2 cells (iAEC2s)^{15,16}. Consistent with our findings in Huh-7 cells, pretreatment of iAEC2s with lactoferrin resulted in a significant reduction in the proportion of SARS-CoV-2 infected cells at MOI 10 (Figure 4F).

194

195 A clinically effective strategy for antiviral therapies uses a combinatorial (or "drug cocktail") approach, where compounds with varying MOAs are concomitantly used to target different stages 196 in the viral life cycle and to minimize the risk of drug resistance from single-agent selective 197 198 pressure. This is especially true for RNA viruses, which are highly variable and can develop drug-199 resistance¹⁷. Given the pronounced single-agent efficacy of lactoferrin, we tested whether combinations with remdesivir or hydroxycholoroguine could improve the overall antiviral activity. 200 201 We found that lactoferrin potentiates the efficacy of both remdesivir (Figure 4G and 202 Supplementary Figure 4A) and hydroxychloroquine (Figure 4H and Supplementary Figure 4B), 203 which are currently explored treatments for SARS-CoV-2 infection. Therefore, combination therapy with lactoferrin could be beneficial in the management of the COVID-19 pandemic by 204 reducing toxicity (e.g., hydroxycholorquine) or consumption (e.g., remdesivir). 205

206 **DISCUSSION**

In this study, we developed an experimental workflow based on high-content imaging and morphological profiling that allows for rapid screening of FDA-approved compounds, leveraging machine learning to determine potential MOA. We identified 15 FDA-approved compounds that limit SARS-CoV-2 infection *in vitro*. Of these, six were previously reported and serve as a benchmark validation of our endpoints and experimental approach, and nine were hitherto unknown. We demonstrate that this approach is versatile (i.e., it can be applied to both transformed and more physiologically-relevant non-transformed cell lines) and can identify the emergent properties of the infection as well as novel phenotypes that can be perturbed through chemical inhibition.

216

A high-content morphological cell profiling approach is superior to image cytometry (tabulating percent positive) and plate reader assays for selecting and prioritizing drugs for repurposing. Here, viral staining is not merely an absolute measure for viral infection (or inhibition) but the starting point for a detailed investigation of infection trajectories and observations of numerous phenotypic targets, including inhibition of syncytia formation, viral entry, or viral replication, and modulation of the host cell. We report compounds with strong antiviral activity against SARS-CoV-2 and also their putative MOA.

224

225 The UMAP embedding was highly effective at visualizing the virally infected cell population and 226 the progression of the viral infection trajectory was clearly visible. We gained insight into the 227 putative antiviral MOAs via inspection of the cluster populations. For thioguanine and clofazimine, 228 increasing concentrations appear to suppress isolated single infected cells (ROI 4) while a small 229 number of syncytia (ROI 3) are still observable (Supplementary Figure 3B), suggesting a 230 replication inhibition MOA. This observation is consistent with the established MOA of both drugs 231 as inhibitors of nucleic acid synthesis^{18,19}. S1RA reduces ROIs 1-4 evenly, but ROI 13 increases (Supplementary Figure 3B: S1RA) and is characterized by increased cytoplasmic nucleic acid 232 staining (Supplementary Figure 3A: ROI 13), suggesting a host-modulation MOA. Lastly, 233 gilteritinib demonstrates an increase in ROI 12 with treatment (Supplementary Figure 3B: 234 235 gilteritinib), a cell cluster defined by large and distributed lipid accumulation (Supplementary 236 Figure 3A: ROI 12). Lipid accumulation, in liver-derived Huh-7 cells, is associated with cytotoxicity 237 and is consistent with reduction in viability with escalating dose (Figure 2B)²⁰.

239 Importantly, our study identified drugs that implicate new molecular targets/pathways in the 240 pathogenesis of SARS-CoV-2 and produce clinically testable and readily translatable hypotheses. As an example, we observed a dose dependent antiviral activity of metoclopramide, a potent 241 242 Dopamine Receptor D2 antagonist used to treat gastroesophageal reflux disease and prevent 243 other gastrointestinal symptoms, including nausea and vomiting²¹. Gastrointestinal symptoms have been increasingly reported in more than half of the patients infected by SARS-CoV-2². 244 Notably, investigational drugs like hydroxychloroquine, lopinavir-ritonavir, tocilizumab and others 245 can be associated with gastrointestinal and hepatic adverse events and hence are not ideal for 246 patients already experiencing severe GI symptoms²². Metoclopramide therefore represents an 247 interesting dual-target therapeutic option for COVID-19 patients. Interestingly, the pro-248 dopaminergic drugs carbidopa, levodopa, and methyldopa promote infection (Supplementary 249 250 Figure 2), suggesting a dopamine-mediated contribution to viral entry or replication. Additionally, 251 all MEK inhibitors exacerbated viral infection up to 300% indicating a causal role of MEK in SARS-CoV-2 pathogenesis. These in vitro observations should be validated through clinical research 252 that examines whether concomitant presence of drug and SARS-CoV-2 exacerbates COVID-19. 253

254

255 As most FDA-approved drugs target human molecular targets, our screen helped identify crucial 256 host factors involved in SARS-CoV-2 infection. Z-FA-FMK, an irreversible inhibitor of cysteine proteases, including cathepsins B, L, and S²³, exhibited potent antiviral activity. A recent report 257 using a pseudovirus indicated cathepsin L is an entry factor of SARS-CoV-2²⁴. The antiviral effect 258 of Z-FA-FMK suggests that cathepsin L is a requirement also in the context of SARS-CoV-2 259 infection and suggests that this molecule could be a useful investigational tool to study virus entry. 260 Similarly, fedratinib is an orally bioavailable semi-selective JAK2 inhibitor, approved by the FDA 261 262 in 2019 for myeloproliferative neoplasm, a rare blood cancer that causes clotting and fibrosis²⁵. JAK-inhibitors have been proposed for COVID-19 to specifically inhibit TH17-mediated 263 inflammatory responses^{26,27}. In addition, JAK-inhibitors have been proposed to block numb-264

associated kinase responsible for clathrin-mediated viral endocytosis²⁸. Several JAK-inhibitors are currently evaluated in clinical trials for COVID-19 management, including with baricitinib²⁹, jakotinib (ChiCTR2000030170), and ruxolitinib (ChiCTR2000029580). Further studies examining these Jak-inhibitors could serve as useful tools in the future to elucidate the involvement of the innate immune response in SARS-CoV-2 infection.

270

271 The sigma receptors (SigmaR1/R2) are permissive chaperones that mediate endoplasmic reticulum stress response and lipid homeostasis³⁰, processes that have been implicated in early 272 stages of hepatitis C viral infection in Huh-7 cells³¹ and coronavirus pathogenesis³². We identified 273 two sigma receptor modulators amiodarone³³ (SigmaR1 IC₅₀: 1.4 nM, SigmaR2 IC₅₀: 1 nM), and 274 S1RA³⁴ (E-52862; SigmaR1 IC₅₀: 17 nM antagonist, SigmaR2 IC₅₀: > 1 μ M) with potent antiviral 275 276 activity, demonstrating IC50 values of 52 nM and 222 nM, respectively, with limited cell toxicity. 277 Amiodarone is approved for treatment of arrhythmias but, like hydroxychloroguine, has potent cardiotoxic side effects through inhibition of the hERG ion channel³⁵ that limit therapeutic potential. 278 S1RA has completed phase II clinical trials for the treatment of neuropathic pain^{36,37}. Although 279 Gordon et al. identified several other sigmaR1/R2 modulators that inhibited SARS-CoV-2 infection 280 281 in Vero-E6 cells, antiviral activity for S1RA was not observed³⁸. This suggests that the activity of S1RA is dependent on host cell factors specific to each cell line and, promisingly, that human 282 283 cells may be more responsive to this compound.

284

Most noteworthy, our screen demonstrates lactoferrin as a SARS-CoV-2 inhibitor *in vitro* with multimodal efficacy. We showed efficacy in multiple cell types, including a non-transformed and clinically relevant iPSC-derived model of alveolar epithelium. Lactoferrin gene expression has been shown previously to be highly upregulated in response to SARS-CoV-1 infection³⁹ and, in addition to enhancing natural killer cell and neutrophil activity, lactoferrin blocks viral entry through binding to heparan sulfate proteoglycans. Interestingly, lactoferrin retains anti-SARS-CoV-2

291 activity 24 hrs p.i., which suggests additional MOA other than simple entry inhibition. Although we 292 cannot conclude a definitive and complete MOA, we show significant host cell modulation through 293 increased expression of several interferon-stimulated genes upon treatment with lactoferrin. 294 Additionally, lactoferrin has been previously shown to decrease the production of IL-6⁴⁰, which is one of the key players of the "cytokine storm" produced by SARS-CoV-2 infection^{41,42}. Importantly, 295 we found that lactoferrin retains activity in both the holo and apo forms, the latter being the 296 297 component of orally available lactoferrin supplements. Orally available lactoferrin could be especially effective in mitigating the gastrointestinal symptoms that are present in COVID-19 298 patients⁴³. The mechanisms may be similar to how lactoferrin reduces human norovirus infection 299 through induction of innate immune responses⁴⁴, especially as lactoferrin gene polymorphisms 300 are associated with increased susceptibility to infectious diarrhea⁴⁵. If lactoferrin reduces viral load 301 302 in the GI tract, it could reduce fecal-oral transmission of COVID-19⁴⁶.

303

Combination therapies are likely to be required for effectively treating SARS-CoV-2 infection, and 304 this approach has already shown some promise. For example, combination therapy with 305 306 interferon beta-1b, lopinavir-ritonavir, and ribavirin showed efficacy against SARS-CoV-2 in a 307 prospective, open-label, randomized, phase 2 trial⁴⁷. We demonstrated in our study that lactoferrin potentiates the antiviral activity of both remdesivir and hydroxychloroquine and could be used as 308 309 a combination therapy with these drugs, which are currently being used or studied for the treatment of COVID-19. Due to its wide availability, limited cost and lack of adverse effects, 310 lactoferrin could be a rapidly deployable option for both prophylaxis and the management of 311 COVID-19. 312

313

Although our findings are promising, further studies are needed to confirm their efficacy in other representative *in vitro* cell lines and/or clinical studies. UMAP analysis provides limited insight to

316 MOA and serve as a basis for future pharmacological studies specific to our compounds in 317 treatment of SARS-CoV-2. These studies are currently ongoing.

318

In conclusion, high-content morphological cell profiling for drug repurposing screening enabled the identification of both novel antivirals efficacious against SARS-CoV-2 and compounds that possibly exacerbate SARS-CoV-2 infection. Furthermore, in contrast to other drug repurposing studies, the assay reported here allowed for the identification of potential MOA, including host cell responses. This approach to preclinical testing has promise for identifying other anti-SARS-CoV-2 drugs, rationally designing therapeutic combinations with multiple MOAs, and deployment of these new combinations in a rapid and systemic fashion.

327 Supplementary Information is available for this paper.

328

329 Correspondence and requests for materials should be addressed to jzsexton@umich.edu

330

331

332 ACKNOWLEDGEMENTS

Funding: University of Michigan Institute for Clinical and Health Research (MICHR) (NCATS -333 UL1TR002240) and its Center for Drug Repurposing. JZS is supported by the National Institute 334 of Diabetes and Digestive and Kidney Diseases (R01DK120623). JWW is supported by the 335 pharmacological sciences training program (PSTP) T32 training grant. CM is supported by Marie-336 Slodowska Curie individual fellowship (GA - 841247) and MICHR Postdoctoral Translational 337 Scholars Program. KDA is supported by the I.M. Rosenzweig Junior Investigator Award from the 338 339 Pulmonary Fibrosis Foundation. JRS is supported by the National Heart, Lung, and Blood Institute 340 (NHLBI – R01HL119215), by the NIAID Novel Alternative Model Systems for Enteric Diseases

(NAMSED) consortium (U19AI116482) and by grant number CZF2019-002440 from the Chan
 Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation.

343

The authors would like to thank Matthew Chess for Amazon AWS support, Kevin Yan and Peyton Uhl at Yokogawa for imaging support, Nick Santoro at the University of Michigan Center for Chemical Genomics. We thank David Egan and Wienand Omta from Core Life Analytics for assisting high content data analytics as well as Philip Cheung and Brian Bolt at ReFactor Biosciences for assistance with HTS data registration. Finally, we thank Tracey Schultz and Dianne Jazdzyk for project management.

350

351 METHODS

352 Cells and Virus. Vero E6, Caco2 and Huh7 cells were maintained at 37°C with 5% CO2 in 353 Dulbecco's Modified Eagle's Medium (DMEM; Welgene), supplemented with 10% heatinactivated fetal bovine serum (FBS), HEPES, non-essential amino-acids, L-glutamine and 1X 354 Antibiotic-Antimycotic solution (Gibco). iPSC (SPC2 iPSC line, clone SPC2-ST-B2, Boston 355 356 University) derived alveolar epithelial type 2 cells (iAEC2s) were differentiated as previously 357 described and maintained as alveolospheres embedded in 3D Matrigel in "CK+DCI" media, as previously described (Jacob et al. 2019). iAEC2s were passaged approximately every two weeks 358 359 by dissociation into single cells via the sequential application of dispase (2mg/ml, Thermo Fisher Scientific, 17105-04) and 0.05% trypsin (Invitrogen, 25300054) and re-plated at a density of 400 360 cells/µl of Matrigel (Corning, 356231), as previously described (Jacob et al. 2019). SARS-CoV-2 361 WA1 strain was obtained by BEI resources and was propagated in Vero E6 cells. Viral titers were 362 determined by TCID50 assays in Vero E6 cells (Reed and Muench method) by microscopic 363 364 scoring. All experiments using SARS-CoV-2 were performed at the University of Michigan under 365 Biosafety Level 3 (BSL3) protocols in compliance with containment procedures in laboratories

approved for use by the University of Michigan Institutional Biosafety Committee (IBC) and
 Environment, Health and Safety (EHS).

368

Viral Quantification. Vero E6, Caco2 and Huh7 cells were seeded in a 48-well plate at 2x10⁴ 369 370 cells/well incubated overnight at 37°C with 5% CO2. Cells were then infected with SARS-CoV-2 WA1 at a multiplicity of infection (MOI) of 0.2. One hour after infection, cells were harvested (day 371 0 of infection) or kept at 37°C for 1, 2 and 3 days p.i. Viral titer determination was performed by 372 TCID50 assay on Vero E6 cells of the total virus (supernatant and intracellular fraction). 373 Alternatively, cells were harvested with Trizol and total cellular and viral RNA was extracted with 374 the ZymoGen Direct-zol RNA extraction kit. Viral RNA was guantified by RT-gPCR using the 375 2019-nCoV CDC qPCR Probe Assay and the probe set N1 (IDT technologies). IFN β , viperin, MX1, 376 377 ISG15, IFITM3 and the housekeeping gene GAPDH mRNA levels were quantified by qPCR with SsoAdvanced[™] Universal SYBR[®] Green Supermix (Bio-Rad) with specific primers (IFNβ: F-378 TTGACATCCCTGAGGAGATTAAGC, R-TCCCACGTACTCCAACTTCCA; MX1: F-379 F-CCAGCTGCTGCATCCCACCC, R-AGGGGCGCACCTT CTCCTCA; ISG15: 380 TGGCGGGCAACGAATT, R-GGGTGATCTGCGCCTTCA; IFITM3: F-TCCCAC 381 382 GTACTCCAACTTCCA, R-AGCACCAGAAACACGTGCACT; GAPDH: F-CTCTGCTCCTCCTGTTCGAC, R-GCGCCCCACCAAGCTCAAGA). 383 Fold increase was 384 calculated by using the $\Delta\Delta$ Ct method over non-infected untreated Huh-7.

385

Viral Infectivity Assay. 384-well plates (Perkin Elmer, 6057300) were seeded with Huh-7 cells at 3000 cells/well and allowed to adhere overnight. Compounds were then added to the cells and incubated for 4 hours. The plates were then transferred to BSL3 containment and infected with SARS-CoV-2 WA1 at a multiplicity of infection (MOI) of 0.2 in a 10 µL addition with shaking to distribute virus. After one hour of absorption, the virus inoculum was removed and media replaced with fresh compound. Uninfected cells and vehicle-treated cells were included as positive and

392 negative control, respectively. Two days post-infection, cells were fixed with 4% PFA for 30 minutes at room temperature, permeabilized with 0.3% Triton X-100 and blocked with antibody 393 buffer (1.5% BSA, 1% goat serum and 0.0025% Tween 20). The plates were then sealed, surface 394 decontaminated, and transferred to BSL2 for staining with the optimized fluorescent dye-set: anti-395 396 nucleocapsid SARS-CoV-2 antibody (Antibodies Online, Cat# ABIN6952432) overnight treatment at 4C followed by staining with secondary antibody Alexa-647 (goat anti-mouse, Thermo Fisher, 397 A21235), Hoechst-33342 Pentahydrate (bis-Benzimide) for nuclei staining (Thermo FIsher, 398 399 H1398), HCS LipidTOX[™] Green Neutral Lipid Stain (Thermo Fisher, H34475), and HCS CellMask[™] Orange for cell delineation (Thermo Fisher H32713). iAEC2 maintained in 3D culture 400 401 were dissociated to single cells and seeded in collagen coated 384-well plates at a seeding density of 8000 cells/well in the presence of 10 µM Y-27632 for the first 48 hours after plating 402 403 (APExBIO, A3008), and grown to confluence over 72 hours. The following infection, compound 404 treatment, and fixing was identical to that of Huh-7. Staining protocol for the iAEC2s differed slightly with the addition of an anti-acetylated tubulin primary antibody (Cell Signaling, 5335), 405 instead of HCS CellMask Orange, and the use of an additional secondary Alexa 488 antibody 406 407 (donkey anti-rabbit, Jackson ImmunoResearch, 711-545-152).

408

409 **Compound Library.** The compound library deployed for drug screening was created using the 410 FDA-Approved Drugs Screening Library (Item No. 23538) from Cayman Chemical Company. This library of 875 compounds was supplemented with additional FDA approved drugs and rationally 411 included clinical candidates from other vendors including MedChemExpress, Sigma Aldrich, and 412 413 Tocris. Our library was formatted in five 384-well compound plates and was dissolved in DMSO 414 at 10 mM. Hololactoferrin (Sigma Aldrich, L4765), apolactoferrin (Jarrow Formulas, 121011) and transferrin (Sigma Aldrich, T2036) were handled separately and added manually in cell culture 415 media. Dilution plates were generated for qHTS at concentrations of 2 mM, 1 mM, 500 µM, 250 416 417 μ M and 50 μ M.

418

qHTS Primary Screen and Dose Response Confirmation. For the qHTS screen, compounds
were added to cells using a 50 nL pin tool Caliper Life Sciences Sciclone ALH 3000 Advanced
Liquid Handling system at the University of Michigan Center for Chemical Genomics (CCG).
Concentrations of 2 µM, 1 µM, 500 nM, 250 nM and 50 nM were included for the primary screen.
Post qHTS screen, all compounds were dispensed using an HP D300e Digital Compound
Dispenser and normalized to a final DMSO concentration of 0.1% DMSO. Confirmation dose
response was performed in triplicate and in 10-point:2-fold dilution.

426

427 Imaging. Stained cell plates were imaged on both Yokogawa CQ1 and Thermo Fisher CX5 high 428 content microscopes with a 20X/0.45NA LUCPIan FLN objective. Yokogawa CQ1 imaging was performed with four excitation laser lines (405nm/488nm/561nm/640nm) with spinning disc 429 430 confocal and 100ms exposure times. Laser power was adjusted to yield optimal signal to noise ratio for each channel. Maximum intensity projection images were collected from 5 confocal 431 planes with a 3 micron step size. Laser autofocus was performed and nine fields per well were 432 433 imaged covering approximately 80% of the well area. The Thermofisher CX5 with LED excitation (386/23nm, 485/20nm, 560/25nm, 650/13nm) was also used and exposure times were optimized 434 to maximize signal/background. Nine fields were collected at a single Z-plane as determined by 435 image-based autofocus on the Hoechst channel. The primary gHTS screen was performed using 436 437 CX5 images and all dose-response plates were imaged using the CQ1.

438

Image Segmentation and feature extraction. The open source CellProfiler software was used
in an Ubuntu Linux-based distributed Amazon AWS cloud implementation for segmentation,
feature extraction and results were written to an Amazon RDS relational database using MySQL.
A pipeline was developed to automatically identify the nuclei, cell, cytoplasm, nucleoli, neutral

lipid droplets and syncytia for feature extraction. Multiple intensity features and radial distributions
were measured for each object in each channel and cell size and shape features were measured.
Nuclei were segmented using the Hoechst-33342 image and the whole cell mask was generated
by expanding the nuclear mask to the edge of the Cell Mask Orange image. **Data Pre-Processing**. Cell level data were pre-processed and analyzed in the open source

Knime analytics platform⁴⁸. Cell-level data was imported into Knime from MySQL, drug treatment metadata was joined and features were centered and scaled. Features were pruned for low variance (<5%) and high correlation (>95%) and resulted in 660 features per cell.

452

453 Statistical methods and hypothesis testing. Dose-response curves were fit and pairwise
454 differences between experimental conditions were tested using Prism (Graphpad Software,
455 San Diego, CA, USA). Other statistical tests were performed in the statistical programming
456 language and environment R.

457

Machine Learning - Infectivity score and field-level scoring. Multiple logistic regression 458 as implemented in the statistical language and environment R was used to identify features 459 characteristic of cells within infected wells. Models were fit to cells from infected and 460 uninfected control wells in the first five plate-series of the quantitative high throughput screen. 461 As an independent benchmark, these logistic regression models were validated against a 462 463 manually selected set of individual infected and uninfected cells; features which degraded 464 performance on the benchmark were excluded from the model. The final model included only 465 virus channel intensity features in the cell and cytoplasm ROIs. As a threshold for initial

466 classification, the minimum value from virus-infected cells in the benchmark was used; the467 final decision rule is given in Eq. 1.

468

469 (Eq.1): A cell is infected if (Cells Intensity IntegratedIntensityEdge Virus × 0.1487025 +

470 Cells_Intensity_MeanIntensityEdge_Virus × -38.40196 +

471 Cells_Intensity_MaxIntensityEdge_Virus × 42.70269 +

472 Cytoplasm_Intensity_StdIntensity_Virus × 42.54849) ≥ 1.525285

473

474 Then, individual field images from the infected control were categorized as confirmed-infected when the mean feature values, across all cells in the field, were above the threshold in Eq. 1. 475 Using mean values for all 660 cell-profiler features in each field, a random forest classifier 476 was trained to predict a probability of membership in the category of uninfected control fields 477 vs confirmed-infected fields. The output of this random forest classifier is reported as 478 "Probpos" (for the positive, uninfected control), throughout. Field level mean/median feature 479 values were computed and a random forest model was fit between the positive control (32 480 uninfected wells) and the negative control (32 infected wells, 0.1% DMSO vehicle treated) 481 with 80/20 cross validation. The compound treated wells were scored with the RF model and 482 the efficacy score was normalized to the individual plate. 483

484

485 **UMAP embedding**. The embed_umap application of MPLearn (v0.1.0, 486 https://github.com/momeara/MPLearn) was used to generate UMAP embeddings. Briefly, each 487 for a set of cells, each feature was per-plate standardized and jointly orthogonalized using 488 sklearn.IncrementalPCA(n_components=379, batch_size=1000). Then features were embedded

489 into 2-dimensions using umap-learn (v0.4.1)(McInnes et al. 2018) with 490 umap.UMAP(n components=2, n neighbors=15, min dist=0, init='spectral', low memory=True, verbose=True). Embeddings were visualized using Holovies Datashader (v1.12.7)⁴⁹, using 491 histogram equalization and the viridis color map. Visualizing subsets was done in JMP Pro 14. 492 493

494 Data analytics. HC Stratominer (Core Life Analytics, Utrecht NL) was used as an independent 495 method for hit-calling and performs fully automated/streamlined cell-level data pre-processing and 496 score generation. IC Stratominer was also used to fit dose response curves for qHTS. 497 Compound registration and assay data registration were performed using the open source 498 ACAS platform (Refactor BioSciences github <u>https://github.com/RefactorBio/acas</u>).

499

500 Dose-response analysis and compound selection. In gHTS screening, a compound was selected to be carried forward into full dose response confirmation when meeting one of the 501 following criteria: 1) Probpos greater than 0.75 for the median field in at least three concentrations, 502 with per-field cell counts at least 60% of the positive control, and without an observed standard 503 504 deviation in Probpos across-fields-in-the-well of 0.4 or greater, 2) a dose-response relationship 505 with Probpos was observed (by inspection) across the five concentrations tested, including 506 compounds with Propbos greater than 0.90 at the two highest concentrations, or 3) compounds 507 of interest not meeting this criteria were carried forward if reported positive in the literature or were 508 being evaluated in clinical trials for COVID-19.

509

510 **Dose response analysis in the confirmation and combinatorial screening.** Due to the spatial 511 inhomogeneity of infected cells across a single well, approximately half of the fields were 512 undersaturated, leading to a consistent distribution in Probpos that saturates in the top third of 27

513	rank-ordered fields (from 9 fields and triplicate wells) for each concentration tested. The Probpos
514	effect for a compound concentration was tabulated by averaging the top third of rank ordered
515	fields. Outlier fields with high Probpos values were visually inspected and eliminated if artifacts
516	(segmentation errors or debris) were observed. Cells treated with known fluorescence drugs
517	including Clofazimine, were confirmed to not have spectral interference. Dose response curves
518	were fit with Graphpad Prism using a semilog 4-parameter variable slope model.
519	
520	

529 FIGURES AND LEGENDS




Figure 1. Morphological profiling of SARS-CoV-2 infected Huh-7 cells (MOI of 0.2 for 48 hrs). Center image: representative field with nuclei (cyan), neutral lipids (green), and SARS-CoV-2 NP protein (magenta). Through feature extraction key traits of SARS-CoV-2 infection were characterized with multinucleated syncytia (top left) and abundant nucleoli (bottom left) from HCS CellMask Orange channel. Cell viral compartmentalization (top right) with cytoplasmic protrusions (bottom right) from SARS-CoV-2 NP channel. Representative image was acquired on a Yokogawa CQ1 high-content imager and visualized with Fiji ImageJ package.

538

- 539
- 540
- 541
- 542
- 543




Figure 2. a) Schematic representation of the anti-SARS-CoV-2 therapy discovery effort. 1)
Compounds are administered to cells cultured on 384-well plates infected with SARS-CoV-2.
Each plate contains 24 negative (infected) and 24 positive (non-infected) control wells to control
for plate-to-plate variation. 2) Cells are fixed, stained, and imaged. Images are analyzed through

a Cell Profiler-based pipeline which segments nuclei, cell boundaries, neutral lipid content and viral syncytia formation while extracting features of these cellular compartments. 3) Dose-response curves are calculated through multivariate-analysis to define per-image viral infectivity 4) Machine learning models are built around positive and negative control wells based on extracted features and applied to each drug condition. 5) Models inform on individual compound mode(s) of antiviral action through obtained features 6) confirmed antiviral hits; b) Dose-response curves of 15 hits of the drug screening. Graphs represent median SEM of 10-point 1:2 dilution series of selected compounds for N=3 biological replicates. IC₅₀ were calculated based on normalization to the control and after fitting in GraphPad Prism.




Figure 3. a) 2 dimensional UMAP embedding of two million individual cells by 379 morphological 586 features consisting of uninfected (PC), infected (NC), or infected and treated with 12 FDA 587 588 approved and clinical candidate drug screening hits across 10 doses. b) Cluster regions of interest (ROI) in the UMAP are highlighted including infected syncytial (ROI 3) and isolated (ROI 4) cells 589 590 and non-infected mitotic (ROI 6), normal (ROI 10), scattered lipid (ROI 11), and cytoplasm punctate (ROI 12) cells. c) For six ROIs, a representative cell is shown by nuclear (upper-left), 591 592 cell boundary (upper-right), neutral lipid (lower-left), and SARS-CoV-2 nucleocapsid (lower-right) 593 channels. Below, the cell count across each treatment and dose is shown as a heat-map, where the dose-responsive behavior for ROIs 3 and 4 are visible. 594




Figure 4. Lactoferrin blocks SARS-CoV-2 replication at different stages of the viral cycle. a) Huh-7 cells were treated with lactoferrin (0 to 2.3 μ M) and infected with SARS-CoV-2 (MOI of 0.2) in a 384-well plate. Plates were imaged using automated fluorescence microscopy and processed

599 using our image analysis pipeline to determine percent viral inhibition. Graph indicates a dose-600 response (RED, IC_{50} = 308 μ M). Cell viability is depicted in black. b) Huh-7 were infected with SARS-CoV-2 (MOI of 1, 5 and 10; MOI of 0 indicates non-infected cells) and treated with 2.3 µM 601 602 of Lactoferrin at 1 and 24hrs p.i. Bars indicate the percentage of infected cells in different 603 conditions. Data is an average of 8 replicates. Statistical significance determined using multiple T-test with the Bonferroni-Dunn method, with alpha = 0.05. Except for MOI of 0, all conditions 604 605 (Untreated vs Lactoferrin, 1 hr or Untreated vs Lactoferrin, 24 hr) differ at P<0.0001. c-d) 2.5x10⁴ Huh-7 cells were infected with SARS-CoV-2 at MOI of 0.2. 48 hrs p.i., cells were harvested and 606 RNA was extracted. Viral genome copies were calculated with an absolute quantification method 607 (standard curve) (c) and mRNA levels of cellular IFNβ, MX1, ISG15 and IFITM3 (d) were 608 calculated with $\Delta\Delta$ Ct over non-infected Huh-7. Data are average, SD of N=2 biological replicates 609 610 with n=3 technical replicates each. Statistical significance determined using multiple T-test with 611 the Bonferroni-Dunn method, with alpha = 0.05. *P<0.001. e) Percentage of SARS-CoV-2 infected Huh-7 cells upon treatment with apolactoferrin, hololactoferrin, and transferrin at a concentration 612 of 2.3 µM. f) Percentage of infected iAEC2 48 hrs p.i. at MOI of 10 upon treatment with remdesivir 613 614 (50 nM), lactoferrin (1.2µM), and remdesivir/lactoferrin (25 nM/600 nM) combination treatment. 615 Error bars shown are SEM. Significance was calculated using Kruskal-Wallis test followed by Dunn's multiple comparison test. *P<0.05 and ***P<0.001. g) and h) 2-dimensional dose response 616 617 heat maps of lactoferrin (0 to 2.3 μ M) in combination with remdesivir and hydroxychloroquine (0 to 30 nM and 0 to 10 µM, respectively). Remdesivir combination was evaluated with a 0.2 MOI 618 and HCQ was evaluated with a MOI of 10 leading to a relative shift in lactoferrin potency. 619

620

621

622

624 SUPPLEMENTARY INFORMATION

- 625 Supplementary Figure 1: Screening assay optimization
- 626 Supplementary Figure 2: Compounds exacerbating SARS-CoV2 infection
- 627 Supplementary Figure 3: Features of UMAP regions of interest (ROI)
- 628 Supplementary Figure 4: Combinatory effects of remdesivir and hydroxycholoroquine with

629 lactoferrin

- 630 Supplementary Table 1: Compound Deep Dives
- 631 Supplementary File 1: Compound library details
- 632 Supplementary File 2: 3D reconstruction video of infected cells

650 **REFERENCES**

- 1. Xiao, F. *et al.* Evidence for Gastrointestinal Infection of SARS-CoV-2. *Gastroenterology*
- 652 (2020). doi:10.1053/j.gastro.2020.02.055
- 2. Lin, L. *et al.* Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. *Gut*
- 654 (2020). doi:10.1136/gutjnl-2020-321013
- 655 3. Avula, A. et al. COVID-19 presenting as stroke. Brain. Behav. Immun. (2020).
- 656 doi:10.1016/j.bbi.2020.04.077
- 4. Kochi, A. N., Tagliari, A. P., Forleo, G. B., Fassini, G. M. & Tondo, C. Cardiac and
- arrhythmic complications in patients with COVID-19. Journal of Cardiovascular
- 659 *Electrophysiology* (2020). doi:10.1111/jce.14479
- 5. Mulangu, S. *et al.* A randomized, controlled trial of Ebola virus disease therapeutics. *N.*
- 661 Engl. J. Med. (2019). doi:10.1056/NEJMoa1910993
- 662 6. Oprea, T. I. *et al.* Drug repurposing from an academic perspective. *Drug Discovery*
- 663 *Today: Therapeutic Strategies* (2011). doi:10.1016/j.ddstr.2011.10.002
- 664 7. Chu, H. et al. Comparative tropism, replication kinetics, and cell damage profiling of
- 665 SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility,
- and laboratory studies of COVID-19: an observational study. *The Lancet Microbe* (2020).
- 667 doi:10.1016/s2666-5247(20)30004-5
- 668 8. Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is
- Blocked by a Clinically Proven Protease Inhibitor. *Cell* (2020).
- 670 doi:10.1016/j.cell.2020.02.052
- 9. Riva, L. *et al.* A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals.
- *bioRxiv* (2020). doi:10.1101/2020.04.16.044016
- 10. Katie Heiser *et al.* Identification of potential treatments for COVID-19 through artificial
- 674 intelligence enabled phenomic analysis of human cells infected with SARS-CoV-2.
- *bioRxiv* (2020). doi:10.1101/2020.04.21.054387

676	11.	Jeon, S. et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-
677		approved drugs. Antimicrob. Agents Chemother. (2020). doi:10.1128/AAC.00819-20
678	12.	McInnes, L., Healy, J., Saul, N. & Großberger, L. UMAP: Uniform Manifold Approximation
679		and Projection. J. Open Source Softw. (2018). doi:10.21105/joss.00861
680	13.	Lang, J. et al. Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan
681		sulfate proteoglycans. PLoS One (2011). doi:10.1371/journal.pone.0023710
682	14.	Siqueiros-Cendón, T. et al. Immunomodulatory effects of lactoferrin. Acta
683		Pharmacologica Sinica (2014). doi:10.1038/aps.2013.200
684	15.	Jacob, A. et al. Derivation of self-renewing lung alveolar epithelial type II cells from
685		human pluripotent stem cells. Nat. Protoc. (2019). doi:10.1038/s41596-019-0220-0
686	16.	Hurley, K. et al. Reconstructed Single-Cell Fate Trajectories Define Lineage Plasticity
687		Windows during Differentiation of Human PSC-Derived Distal Lung Progenitors. Cell
688		Stem Cell (2020). doi:10.1016/j.stem.2019.12.009
689	17.	Yeni, P. Update on HAART in HIV. in <i>Journal of Hepatology</i> (2006).
690		doi:10.1016/j.jhep.2005.11.021
691	18.	Evans, W. E. Pharmacogenetics of Thiopurine S-Methyltransferase and Thiopurine
692		Therapy. in <i>Therapeutic Drug Monitoring</i> (2004). doi:10.1097/00007691-200404000-
693		00018
694	19.	Arbiser, J. L. & Moschella, S. L. Clofazimine: A review of its medical uses and
695		mechanisms of action. Journal of the American Academy of Dermatology (1995).
696		doi:10.1016/0190-9622(95)90134-5
697	20.	Alghamdi, S., Leoncikas, V., Plant, K. E. & Plant, N. J. Synergistic interaction between
698		lipid-loading and doxorubicin exposure in Huh7 hepatoma cells results in enhanced
699		cytotoxicity and cellular oxidative stress: Implications for acute and chronic care of obese
700		cancer patients. Toxicol. Res. (Camb). (2015). doi:10.1039/c5tx00173k
701	21.	Hibbs, A. M. & Lorch, S. A. Metoclopramide for the treatment of gastroesophageal reflux

702		disease in infants: A systematic review. <i>Pediatrics</i> (2006). doi:10.1542/peds.2005-2664
703	22.	Hajifathalian, K. et al. SARS-COV-2 infection (coronavirus disease 2019) for the
704		gastrointestinal consultant. World J. Gastroenterol. (2020). doi:10.3748/wjg.v26.i14.1546
705	23.	Roscow, O., Ganassin, R., Garver, K. & Polinski, M. Z-FA-FMK demonstrates differential
706		inhibition of aquatic orthoreovirus (PRV), aquareovirus (CSRV), and rhabdovirus (IHNV)
707		replication. Virus Res. (2018). doi:10.1016/j.virusres.2017.11.024
708	24.	Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its
709		immune cross-reactivity with SARS-CoV. Nat. Commun. (2020). doi:10.1038/s41467-
710		020-15562-9
711	25.	Pardanani, A. et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently
712		inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
713		<i>Leukemia</i> (2007). doi:10.1038/sj.leu.2404750
714	26.	Wu, D. & Yang, X. O. TH17 responses in cytokine storm of COVID-19: An emerging
715		target of JAK2 inhibitor Fedratinib. J. Microbiol. Immunol. Infect. (2020).
716		doi:10.1016/j.jmii.2020.03.005
717	27.	Zhang, W. et al. The use of anti-inflammatory drugs in the treatment of people with
718		severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists
719		from China. Clinical Immunology (2020). doi:10.1016/j.clim.2020.108393
720	28.	Stebbing, J. et al. COVID-19: combining antiviral and anti-inflammatory treatments. The
721		Lancet Infectious Diseases (2020). doi:10.1016/S1473-3099(20)30132-8
722	29.	Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized
723		Patients. (2020). Available at: https://clinicaltrials.gov/ct2/show/NCT04321993.
724	30.	Delprat, B., Crouzier, L., Su, T. P. & Maurice, T. At the Crossing of ER Stress and MAMs:
725		A Key Role of Sigma-1 Receptor? in Advances in Experimental Medicine and Biology
726		(2020). doi:10.1007/978-3-030-12457-1_28
727	31.	Friesland, M., Mingorance, L., Chung, J., Chisari, F. V. & Gastaminza, P. Sigma-1

728 Receptor Regulates Early Steps of Viral RNA Replication at the Onset of Hepatitis C Virus Infection. J. Virol. (2013). doi:10.1128/jvi.03557-12 729 730 32. Fung, T. S. & Liu, D. X. Coronavirus infection, ER stress, apoptosis and innate immunity. Frontiers in Microbiology (2014). doi:10.3389/fmicb.2014.00296 731 732 33. Moebius, F. F., Reiter, R. J., Hanner, M. & Glossmann, H. High affinity of sigma1-binding sites for sterol isomerization inhibitors: Evidence for a pharmacological relationship with 733 the yeast sterol C8-C7 isomerase. Br. J. Pharmacol. (1997). doi:10.1038/sj.bjp.0701079 734 Díaz, J. L. *et al.* Synthesis and biological evaluation of the 1-arylpyrazole class of σ 1 735 34. receptor antagonists: Identification of 4-{2-[5-methyl-1- (naphthalen-2-yl)-1H-pyrazol-3-736 yloxy]ethyl}morpholine (S1RA, E-52862). J. Med. Chem. (2012). doi:10.1021/jm3007323 737 738 35. Torres, V. et al. QT prolongation and the antiarrhythmic efficacy of amiodarone. J. Am. 739 Coll. Cardiol. (1986). doi:10.1016/S0735-1097(86)80272-8 740 36. Vidal-Torres, A. et al. Effects of the selective sigma-1 receptor antagonist S1RA on formalin-induced pain behavior and neurotransmitter release in the spinal cord in rats. J. 741 *Neurochem.* (2014). doi:10.1111/jnc.12648 742 743 37. Gris, G. et al. The selective sigma-1 receptor antagonist E-52862 attenuates neuropathic 744 pain of different aetiology in rats. Sci. Rep. (2016). doi:10.1038/srep24591 Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug 745 38. 746 repurposing. Nature (2020). doi:10.1038/s41586-020-2286-9 39. Reghunathan, R. et al. Expression profile of immune response genes in patients with 747 severe acute respiratory syndrome. BMC Immunol. (2005). doi:10.1186/1471-2172-6-2 748 40. Cutone, A. et al. Lactoferrin prevents LPS-induced decrease of the iron exporter 749 750 ferroportin in human monocytes/macrophages. BioMetals (2014). doi:10.1007/s10534-751 014-9742-7 Conti, P. et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung 752 41. inflammation by COVID-19: anti-inflammatory strategies. Journal of biological regulators 753

and homeostatic agents (2020). doi:10.23812/CONTI-E.

- 755 42. Lagunas-Rangel, F. A. & Chávez-Valencia, V. High IL-6/IFN-γ ratio could be associated
- with severe disease in COVID-19 patients. *Journal of Medical Virology* (2020).
- 757 doi:10.1002/jmv.25900
- 43. Han, C. *et al.* Digestive Symptoms in COVID-19 Patients With Mild Disease Severity:
- 759 Clinical Presentation, Stool Viral RNA Testing, and Outcomes. Am. J. Gastroenterol.
- 760 (2020). doi:10.14309/ajg.00000000000664
- 761 44. Oda, H. et al. Antiviral Effects of Bovine Lactoferrin on Human Norovirus. Biochem. Cell
- 762 Biol. (2020). doi:10.1139/bcb-2020-0035
- 45. Mohamed, J. A. *et al.* A Novel Single-Nucleotide Polymorphism in the Lactoferrin Gene Is
- Associated with Susceptibility to Diarrhea in North American Travelers to Mexico. *Clin.*
- 765 Infect. Dis. (2007). doi:10.1086/512199
- 46. Gu, J., Han, B. & Wang, J. COVID-19: Gastrointestinal Manifestations and Potential
- Fecal–Oral Transmission. *Gastroenterology* (2020). doi:10.1053/j.gastro.2020.02.054
- 47. Hung, I. F.-N. et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and
- ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label,
- randomised, phase 2 trial. *Lancet* (2020). doi:10.1016/s0140-6736(20)31042-4
- 48. Berthold, M. R. *et al.* KNIME: The konstanz information miner. in *4th International*
- 772 Industrial Simulation Conference 2006, ISC 2006 (2006). doi:10.1007/978-3-540-78246-
- 773 9_38
- 49. Stevens, J.-L., Rudiger, P. & Bednar, J. HoloViews: Building Complex Visualizations
- Easily for Reproducible Science. in *Proceedings of the 14th Python in Science*
- 776 *Conference* (2015). doi:10.25080/majora-7b98e3ed-00a
- 777